The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2018 | Cereblon pathway-mediated IMiD resistance in multiple myeloma
CRISPR technology is being used to define mechanisms of multiple myeloma (MM) drug resistance. Here, Constantine Mitsiades, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, discusses his group’s work in this exciting area, investigating Cereblon pathway-mediated resistance to thalidomide and its derivatives, lenalidomide and pomalidomide. He concludes by highlighting what can be done in future trials to select patients who do not have this resistance. This interview took place at the Myeloma 2018 meeting, held in San Diego, CA.
